Moxifloxacin Utilization and the Efficacy of Hand-Held Electronic Data Collection in Tertiary Care Settings

The systematic assessment of how medications are prescribed, dispensed, and administered within a healthcare environment is a critical component of institutional quality assurance. Medication-use evaluation, frequently referred to as drug use evaluation (DUE), serves as a structured process designed to ensure that medications are used appropriately and in accordance with evidence-based guidelines. A prominent example of this process is the evaluation of moxifloxacin, a potent fluoroquinolone antibiotic, particularly within high-capacity tertiary care facilities. The implementation of such evaluations often requires the synthesis of clinical criteria and innovative data-collection methodologies to determine if drug utilization aligns with approved indications or if patterns of over-utilization exist that could potentially drive antimicrobial resistance.

The integration of technology into these evaluations represents a significant shift in pharmaceutical practice. Traditionally, DUE processes relied on manual chart reviews, which were time-consuming and prone to lag. The introduction of hand-held electronic devices, such as personal digital assistants (PDAs) and their modern successors, allows for the real-time collection of patient data during routine care. This transition from paper-based to electronic data collection not only accelerates the gathering of information but also facilitates the rapid synchronization of data into centralized databases for analysis. By examining the specific application of moxifloxacin at Vancouver General Hospital, one can observe the entire lifecycle of a medication-use evaluation, from the hypothesis of over-utilization to the rigorous categorization of clinical outcomes.

The Framework of the Moxifloxacin Observational Study

The evaluation conducted at Vancouver General Hospital provides a detailed blueprint for performing an observational DUE. This specific hospital, characterized as a 955-bed tertiary care facility, serves as a complex environment where a wide variety of medical specialties intersect, increasing the likelihood of varied prescribing habits. The study was initiated based on the observation that the use of moxifloxacin (marketed as Avelox) had increased since its introduction to the hospital formulary in 2002. This increase prompted a hypothesis that the drug was being over-utilized and that significant opportunities existed to optimize its application.

The study was executed over a precise 4-week window, running from February 17 to March 16, 2007. During this period, any inpatient who received at least one dose of moxifloxacin was enrolled in the study. To determine the appropriateness of the drug's use, the researchers developed evidence-based assessment criteria. The primary goal, or primary endpoint, was to calculate the proportion of moxifloxacin use that fell under approved first-line indications.

Technological Integration in Data Collection

One of the most innovative aspects of this medication-use evaluation was the evaluation of the feasibility of using a PDA device as the primary data-collection tool. The transition to electronic tools is designed to streamline the workflow of the healthcare provider while maintaining the integrity of the data.

The technical workflow for data extraction and management involved several distinct stages:

• Initial Data Capture: Data were collected using PDAs during routine patient care, allowing for point-of-care documentation.
• Synchronization: The PDAs were synchronized with a central database to ensure that information was captured in a timely manner.
• Database Construction: The final database was built using Microsoft Access 2003.
• Data Merging: Patient records were exported from Pendragon Forms into Microsoft Access 2003. This allowed the researchers to merge the PDA-collected data with existing information extracted from the hospital’s PCIS (Patient Care Information System).

The impact of this system is far-reaching. Such a framework allows for the timely review of drug utilization immediately following the introduction of a new medication, the implementation of a new drug policy, or the issuance of a drug safety alert. Furthermore, the flexibility of this system means it can be custom-tailored to various point-of-care devices, including the iPhone, iPad, iPod Touch, or Blackberry.

Patient Demographics and Clinical Profile

The study included a total of 132 patients, providing a diverse snapshot of the hospital population utilizing moxifloxacin. The demographic and clinical data reveal a patient population that is generally older and often presents with complex comorbidities.

Table 1: Patient Demographic and Baseline Characteristics

The medication-use evaluation also meticulously tracked drug allergies and intolerances, as these often dictate the choice of a first-line antibiotic. Many patients may receive moxifloxacin not because it is the primary choice for the infection, but because they cannot tolerate other classes of antibiotics.

Drug Allergy and Intolerance Distribution:

• No known drug allergies: 91 patients (68.9%)
• Penicillin/cephalosporin: 26 patients (19.7%)
• Sulfonamide: 15 patients (11.4%)
• Macrolide: 4 patients (3.0%)
• Ciprofloxacin: 3 patients (2.3%)
• Clindamycin: 3 patients (2.3%)
• Tetracycline: 2 patients (1.5%)
• Acyclovir: 1 patient (0.8%)
• Bacitracin: 1 patient (0.8%)
• Metronidazole: 1 patient (0.8%)
• Quinine sulphate: 1 patient (0.8%)

Comorbidity and Clinical Context

The appropriateness of moxifloxacin use cannot be judged in isolation; it must be viewed through the lens of the patient's overall health status. The study identified several key comorbidities that may have influenced the decision to prescribe this specific fluoroquinolone.

The distribution of comorbidities among the 132 patients was as follows:

• Respiratory disease (including asthma and COPD): 40 patients (30.3%)
• Immunocompromised state: 37 patients (28.0%)
• Hospitalized more than 48 hours before pneumonia: 35 patients (26.5%)
• No comorbidities: 24 patients (18.2%)
• Diabetes mellitus: 21 patients (15.9%)
• Recent non-fluoroquinolone antibiotic use (within 3 months): 21 patients (15.9%)
• Other concomitant infection: 15 patients (11.4%)
• Recent hospitalization: 14 patients (10.6%)
• Recent fluoroquinolone antibiotic use (within 3 months): 12 patients (9.1%)
• Arrhythmia or use of antiarrhythmic drugs: 9 patients (6.8%)
• Chronic renal failure: 6 patients (4.5%)
• Ventilated ICU patient: 6 patients (4.5%)
• Seizure disorder (within 3 months): 3 patients (2.3%)

These factors are critical because certain conditions, such as arrhythmia or seizure disorders, can be exacerbated by fluoroquinolone use, making the evaluation of appropriateness even more vital for patient safety.

Distribution Across Hospital Services

The use of moxifloxacin spanned nearly every department within the tertiary care facility, highlighting its broad application across various medical and surgical disciplines.

Table 2: Distribution of Moxifloxacin Use by Service

The high concentration of use in general medicine and respiratory services aligns with the primary indications for the drug, particularly the treatment of pneumonia and bronchitis.

Definitions and Criteria for Evaluation

To maintain objectivity in the medication-use evaluation, the study established strict definitions for the type of therapy and the resulting clinical outcomes. These definitions allow the evaluators to categorize how the drug was used and whether that use resulted in a positive health outcome for the patient.

The therapy was categorized into three distinct types:

• Directed therapy: This occurs when moxifloxacin is initiated based on culture and sensitivity results that target a known, identified pathogen.
• Empirical therapy: This occurs when the drug is initiated based on the expected pathogens likely to be causing the infection or while culture and sensitivity results are still pending.
• Prophylactic therapy: This occurs when the drug is administered specifically to prevent an infection from occurring.

Simultaneously, clinical outcomes were measured to determine the efficacy of the treatment:

• Success: Defined as the complete resolution of signs and symptoms of infection, including improvement of all baseline parameters by the time of discharge or within the hospital. It also includes cases where there were significantly fewer signs and symptoms.
• Indeterminate: This classification is used when the patient's health status cannot be evaluated due to insufficient data, such as when a patient is discharged without a clear status update.
• Failure: Defined as the persistence or worsening of signs and symptoms of infection, which necessitates the initiation of an alternative anti-infective agent, or a lack of significant remission in baseline parameters.

Results and Evidence-Based Analysis

The findings of the study provided a clear picture of the concordance between moxifloxacin use and evidence-based guidelines. Out of the 132 patients, 89 patients (67%) received the medication for approved first-line indications.

The specific first-line indications identified in the study were:

• Community-acquired pneumonia: 57% of the patients.
• Acute exacerbation of chronic bronchitis: 10% of the patients.

These results suggest that while a majority of the use was appropriate, there remained a portion of the population receiving the drug for indications that were not first-line. The overarching intent of the evaluation was to limit the overuse of moxifloxacin outside of community-associated respiratory infections to prevent the development of antimicrobial resistance.

Limitations and Contextual Factors

A critical component of any medication-use evaluation is the acknowledgment of limitations to ensure the results are not overgeneralized. The Vancouver General Hospital study noted several constraints that must be considered when applying these findings to other contexts.

First, the study was limited to a single facility. Because prescribing habits and patient demographics vary by institution, the results regarding moxifloxacin utilization might not be directly applicable to other hospitals. However, the evidence-based assessment criteria developed for the study can be adopted by other sites to review their own prescribing patterns.

Second, the duration of the study was only four weeks. This narrow window provides a cross-section of drug utilization at that specific time but may not represent the patterns of moxifloxacin usage across an entire calendar year.

Third, the "place of therapy" for the drug was determined based on local practices. While the assessment criteria were derived from broader literature, the local implementation of these criteria is influenced by the specific institutional culture and available alternatives.

Finally, the researchers noted that drug allergies and resistance to other antibiotics can complicate the assessment of "appropriateness." In cases where a patient is allergic to first-line agents or where the infection is resistant to standard treatments, moxifloxacin may be considered an appropriate first-line therapy for conditions that would normally require an alternative treatment.

The Role of Supporting Organizations in Pharmacy Practice

The ability to conduct such rigorous medication-use evaluations is often bolstered by the resources and advocacy provided by professional organizations. The ASHP Foundation, for example, provides essential resources to support Medication-Use Evaluation. These programs are designed to advance pharmacy practice, enhance medication safety, and improve overall patient outcomes. By providing the framework and resources necessary for pharmacies to evaluate their drug use, these organizations help the profession move forward through evidence-based improvements in clinical care.

Analysis of Clinical Implications

The data from the moxifloxacin DUE demonstrates the inherent tension between the necessity of potent antibiotics and the global threat of antimicrobial resistance. The fact that 67% of patients were receiving the drug for first-line indications suggests a relatively high level of adherence to guidelines, yet the remaining percentage highlights the "grey area" of prescribing. This grey area often consists of the "directed" vs. "empirical" struggle, where clinicians must act quickly to treat a patient before culture results are available.

The success of the PDA-based data collection method indicates that the barrier to performing more frequent DUEs is not necessarily the lack of data, but the method of collection. By reducing the friction associated with data entry and allowing for the synchronization of information with systems like Microsoft Access 2003 and the hospital's PCIS, healthcare institutions can move toward a model of continuous quality improvement.

When analyzing the comorbidities, the high prevalence of respiratory disease (30.3%) and immunocompromised states (28.0%) explains the heavy reliance on moxifloxacin. These populations are at higher risk for severe infections and often require the broad-spectrum coverage provided by fluoroquinolones. However, the intersection of these risks with the drug's potential for serious adverse effects—such as those seen in patients with arrhythmia (6.8%) or renal failure (4.5%)—underscores the necessity of a DUE to ensure that the benefit of the drug outweighs the risk to the individual patient.

Sources

1. ASHP Foundation
2. PubMed Central